'Murderbot' review: Alexander Skarsgård's killer robot comedy is slow to boot up
Security Unit 238776431 is the property of the Company, a powerful mega-conglomerate located in the galaxy's Corporation Rim. Programmed to serve, the heavily armed robot soldier does not love its job. 'I was built to obey humans,' explains SecUnit (Alexander Skarsgård) in the series premiere of Murderbot. 'But humans... well, they're assholes.'
Unbeknownst to its owners, however, this SecUnit — a misanthropic robot in the vein of Marvin the Paranoid Android (The Hitchhiker's Guide to the Galaxy) and Bender (Futurama) — just hacked its 'governor module,' freeing itself from techno-slavery. Though it could kill its human captors and set off on its own, SecUnit does not want to risk discovery as a 'rogue' bot, which would result in being stripped for parts and melted in an acid bath. Choosing instead to bide its time, the SecUnit — which decides to rename itself Murderbot — reluctantly joins its next assignment: Working for a team of researchers from Preservation Alliance, a distant planet that rejects the Corporation Rim's harsh laws and embraces an egalitarian form of government. Murderbot resigns itself to protecting these 'hippie scientists,' though all it really wants to do is watch entertainment 'content' downloaded from the Company's satellite feed.
Murderbot, adapted by Chris and Paul Weitz (About a Boy) from Martha Wells' popular book series, has a hilarious premise, an admirable cast, and a lavish, Apple TV+ budget. It also has a real pacing problem; the first half of the 10-episode season is puzzlingly light on plot momentum and laughs. While the action, characters, and comedy do ultimately gel by the end, viewers will likely have to wait for a season 2 to see Murderbot reach its killer potential.
Preservation Alliance leader Dr. Ayda Mensah (Noma Dumezweni) and her team of scientists — Ratthi (Akshay Khanna), Bharadwaj (Tamara Podemski), Gurathin (David Dastmalchian), Arada (Tattiawna Jones), and her wife, Pin-Lee (Sabrina Wu) — embark on a research expedition to an uninhabited planet with Murderbot in tow. (Though Mensah says her team is 'not comfortable with the idea of a sentient construct being required to work for us,' the Company will not provide insurance for their research project unless the team takes security.) Murderbot has little interest in Mensah and her 'weird' crew. Still, it easily homes in on the team's subtle interpersonal dynamics, as when its pulse-rate monitor identifies a love triangle between Pin-Lee, Ratthi, and Arada. It also quickly realizes that Dr. Gurathin, an 'augmented human' whose brain can perform some computer functions, suspects that it might be rogue.
The unit keeps one 'eye' on the scientists, and the other on its favorite soap opera, The Rise and Fall of Sanctuary Moon, which features a romance between a dashing captain (John Cho) and a beautiful Navigation Bot (DeWanda Wise). But when Mensah discovers that another research team on the planet has been killed by unknown assailants, Murderbot is forced to engage with its 'helpless and useless' clients.
It may be a (literally) heartless machine, but Murderbot shares more in common with its clients than it's willing to admit. Like many humans, it is uncomfortable with sustained eye contact; it would rather take an acid bath than give a speech; and it prefers the company of TV characters to real people. Also, its coworkers drive it up a wall. Unfortunately, the Planetary Alliance gang insist on treating Murderbot like one of the team, inviting it to ride in their transport vehicle (instead of the cargo bay, where SecUnits usually travel) and giving it a crew uniform to wear when its armor is damaged.
Murderbot's struggle to accept being embraced — figuratively and literally — by its human clients, who insist on valuing its input and individuality, is the show's comedic engine. When Murderbot gets really desperate, it searches Sanctuary Moon and other TV shows for examples of small talk ('Tell me, Dr. Arada, what planet are you from originally?'), which it mimics with comical discomfort. For nearly five episodes, though, the Weitz brothers stall their lead character's development by relegating its emotional turmoil to excessive voiceovers. Murderbot's inner monologue can be funny ('I don't have a stomach so I can't throw up, but if I did, I would'), but it also keeps the story in a holding pattern: Mensah and her team try to connect with Murderbot; it stonewalls them while stewing over how annoying they are; repeat.
The debut season of Murderbot is based on the first book in Wells' series, All Systems Red, which clocks in at about 150 pages. I mention this because the Apple TV+ adaptation suffers from 'season-long pilot' syndrome — a common malady in which a new streaming series spends much of its initial 8 to 10 episodes restating its premise. The Weitz brothers, credited as the series' sole writers, hew close to Wells' source material for their adaptation, but there simply isn't enough story to fill 10 episodes, even at around 25 minutes each. As a result, the season is nearly half over before Murderbot's dynamic with its team, and the ongoing mystery about the slaughtered researchers, really start to develop.
When Murderbot finally starts voicing its annoyance to Mensah and the team, the series gets a lot more entertaining. 'I wish I didn't have to, but of course I can hear you,' grouses SecUnit, after Pin-Lee complains about its eavesdropping. "I'm a highly advanced piece of technology.' Skarsgård, a stealth comedic presence in Succession, also puts his Nordic reserve to good use as Murderbot. The actor enhances his character's long inner monologues with his eloquent ice-blue eyes, which can convey emotions ranging from disdain and discomfiture to despair and devotion. Dumezweni makes Mensah believable as both a thoughtful leader and an overly anxious empath prone to panic attacks. And Pen15's Anna Konkle drops in for an amusing turn as Leebeebee, a survivor from the other research team who can't stop speculating about Murderbot's anatomy.
Viewers who stick with Murderbot will be rewarded with a moving finale, one that solidifies the characters' relationship with SecUnit and seems to set up the story from Wells' second book, 2018's Artificial Condition. Apple TV+ has yet to announce a renewal, but the streamer isn't opposed to giving expensive sci-fi series multiple seasons, so it's not unreasonable to believe that Skarsgård's restless robot will be back. Now that Murderbot finally found its voice, it deserves a chance to use it. Grade: B-
The first two episodes of Murderbot premiere Friday, May 16 on Apple TV+.
Read the original article on Entertainment Weekly
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNET
4 hours ago
- CNET
'Murderbot': When to Watch Episode 5 of Apple's New Sci-Fi Comedy Thriller
Alexander Skarsgård as the titular sentient sec bot in Apple TV Plus's sci-fi thriller, Murderbot. Apple TV Plus Murderbot joins the epic list of must-see sci-fi series you can watch on Apple TV Plus. The sci-fi comedy is based on Martha Wells's Hugo—and Nebula Award-winning bestselling series. It follows a self-hacking security robot (or sec bot, for short) programmed to protect its crew while trying to make sense of its newfound sentience. It loves trashy TV but despises human emotions. Alexander Skarsgård leads the series as the cyborg in question. Can the Murderbot keep its free will a secret and serve out its assignment to keep its vulnerable human clients safe? Or will it succumb to its more profound desire: watching futuristic soap operas and pondering its place in the vast, unknowable maw of the universe? Alongside Skarsgård, Noma Dumezweni, David Dastmalchian, Sabrina Wu, Akshay Khanna, Tamara Podemski and Tattiawna Jones star. The Weitz brothers wrote, directed and produced the series; David S. Goyer and Keith Levine are the executive producers. Scroll on to learn the episodic release schedule for Murderbot and more streaming details about the series. Read more: Best Streaming Services of 2025 When to watch Murderbot on Apple TV Plus Murderbot's fifth episode, Rogue War Tracker Infinite, will premiere on Apple TV Plus on Friday, June 6. The remaining episodes will stream on the platform each Friday until the Season 1 finale on July 11. Here's the full episodic schedule: Episode 1: "Free Commerce" -- May 16 "Free Commerce" -- May 16 Episode 2: "Eye Contact" -- May 16 "Eye Contact" -- May 16 Episode 3: "Risk Assessment" -- May 23 "Risk Assessment" -- May 23 Episode 4: "Escape Velocity Protocol" -- May 30 "Escape Velocity Protocol" -- May 30 Episode 5: "Rogue War Tracker Infinite" -- June 6 "Rogue War Tracker Infinite" -- June 6 Episode 6: "Command Feed" -- June 13 "Command Feed" -- June 13 Episode 7: "Complementary Species" -- June 20 "Complementary Species" -- June 20 Episode 8: "Foreign Object" -- June 27 "Foreign Object" -- June 27 Episode 9: "All Systems Red" -- July 4 "All Systems Red" -- July 4 Episode 10: "The Perimeter" -- July 11 If you don't have an Apple device, sign up for the service via Prime Video channels or on your Android device. James Martin/CNET Apple TV Plus Home of Murderbot To watch Murderbot, you will need to sign up for a subscription to Apple TV Plus, which is priced at $10 per month. If you are a new subscriber, you can take advantage of a seven-day free trial. Additionally, if you have purchased a new Apple device, you are eligible for three months of Apple TV+ for free, but you must redeem this offer within 90 days of your purchase. See at Apple TV Plus How to watch Murderbot from anywhere with a VPN If you're traveling abroad and want to keep up with your favorite shows or movies while away from home, a VPN can help enhance your privacy and security when streaming. It encrypts your traffic and prevents your internet service provider from throttling your speeds; they can also be helpful when connecting to public Wi-Fi networks while traveling, adding an extra layer of protection for your devices and logins. VPNs are legal in many countries, including the US and Canada, and can be used for legitimate purposes such as improving online privacy and security. However, some streaming services may have policies restricting VPN usage to access region-specific content. If you're considering a VPN for streaming, check the platform's terms of service to ensure compliance. If you choose to use a VPN, follow the provider's installation instructions, ensuring you're connected securely and in compliance with applicable laws and service agreements. Some streaming platforms may block access when a VPN is detected, so verifying whether your streaming subscription allows VPN usage is crucial.
Yahoo
5 hours ago
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485